Driving clinical impact
Faster, leaner & de-risked
Galenicap is a Belgian-Dutch privately held pharmaceutical development company focused on the development of improved versions of existing medicines (also known as value-added medicines), featuring enhanced efficacy or safety profiles, and potentially offering new therapeutic applications. Our purpose is to deliver superior, cost-effective treatment alternatives to patients, while also presenting substantial opportunities for cost reduction to healthcare providers.
Product portfolio
Galenicap is on a mission to establish a world-class 'product engine' dedicated to the efficient launch and clinical validation of innovate drug reformulation and repurposing concepts. Presently, we are engaged in 12 development programs, spanning a broad range of therapeutic indications including CNS, cardiovascular and infectious diseases, and women's health.
Unlike most 505(b)(2) or hybrid projects that bring minimal innovation, Galenicap pioneers groundbreaking solutions with real clinical impact
Everyone counts
Our vision is to deliver improvements to the healthcare community by increasing access to affordable and more patient-tailored medicines.
At Galenicap, we are dedicated to advancing our commitment to responsible business practices. Our focus on key pillars such as social impact and strong governance, underscores our dedication to health access, equitable medicine pricing, transparent leadership, and fostering diversity and inclusion.
​
We are proud to say that all our team members, collaborators, partners and shareholders share our values.
Latest news & events
Galenicap co-founded Aclathera BV, a specialty pharma dedciated to the development of new cancer treatments
March 28, 2025
Clozathera BV (a Galenicap company) completes financing round to support Phase 1 clinical trial for its lead product
January 6, 2025
Galenicap establishes drug repurposing collaboration with leading Danish university
​
September 2, 2024